Pacira BioSciences, Inc. Chief Administrative Officer Kristen Williams filed a Form 4 on November 17, 2026, reporting the disposition of common stock and cancellation of stock options at the effective time of the company's merger with a Viatris subsidiary.
Key Highlights
- Shares disposed: Williams disposed of 167,062 shares of common stock (including RSUs) on November 17, 2026, at $36.50 per share.
- Merger trigger: The dispositions occurred pursuant to the Agreement and Plan of Merger dated October 8, 2026, among Pacira BioSciences, Viatris Inc., and Peach Purchaser Sub Inc.
- Merger outcome: Peach Purchaser Sub Inc. merged with and into Pacira BioSciences, with Pacira continuing as a wholly owned subsidiary of Viatris.
- RSU treatment: Each outstanding RSU, whether vested or unvested, was canceled and converted into the right to receive cash equal to the number of underlying shares multiplied by the $36.50 offer price, subject to applicable tax withholdings.
- Six stock options canceled: Options with exercise prices of $38.35, $43.54, $47.65, $60.96, $59.39, and $38.74 per share were all disposed of, with zero shares remaining following the transaction.
- Out-of-the-money options: According to the filing, each option with a per-share exercise price greater than or equal to the $36.50 offer price was canceled at the effective time with no consideration payable.
Pacira BioSciences Merger Closes: Williams Reports Full Disposition of Equity Holdings
According to the Form 4 filed with the SEC, Kristen Williams, Chief Administrative Officer of Pacira BioSciences, Inc. (NASDAQ:PCRX), reported the disposition of all her directly held common stock and stock options on November 17, 2026, the effective time of the merger between the company and Peach Purchaser Sub Inc., a subsidiary of Viatris Inc. The filing states that Peach Purchaser Sub Inc. consummated a cash tender offer to purchase all outstanding shares of Pacira BioSciences common stock at $36.50 per share, net of applicable withholding taxes and without interest.
The filing discloses that Williams disposed of 167,062 shares of common stock, including restricted stock unit awards, at the $36.50 offer price. At the effective time, the filing states, each share was "converted into the right to receive the Offer Price." RSUs that were outstanding immediately prior to the effective time, whether vested or unvested, were canceled and converted into the right to receive cash based on the number of underlying shares multiplied by the offer price, subject to applicable tax withholdings.
Williams also held six stock options that were canceled at the effective time. Options with exercise prices below $36.50 per share were converted into the right to receive cash equal to the excess of the offer price over the exercise price, multiplied by the number of shares subject to each option, subject to applicable tax withholdings. The filing notes that options with an exercise price per share greater than or equal to the offer price were canceled with no consideration payable. Following all reported transactions, Williams beneficially owned zero shares of common stock and held zero derivative securities, according to the filing.
What Was Disclosed
Kristen Williams, Chief Administrative Officer of Pacira BioSciences, reported the full disposition of 167,062 shares of common stock and the cancellation of six stock options on November 17, 2026, all resulting from the closing of the company's merger with a Viatris subsidiary at $36.50 per share.




Please wait processing your request...